Clinical Trials
28 trialsIT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma
University of Wisconsin, Madison
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
N.N. Alexandrov National Cancer Centre
SPARE-04
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Neo-CD
Second Affiliated Hospital, School of Medicine, Zhejiang University
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Sun Yat-sen University
Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC
Fudan University
TRIPLE-PATH
Jinling Hospital, China
Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma
Sun Yat-sen University
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
The First Affiliated Hospital of Soochow University
Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
Shandong Cancer Hospital and Institute
VVSHIP
Sixth Affiliated Hospital, Sun Yat-sen University
The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC
Chongqing University Cancer Hospital
A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma
Sun Yat-sen University
CRITâ…¡
Sixth Affiliated Hospital, Sun Yat-sen University
Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
University of Pittsburgh
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Sun Yat-sen University
SPARC-1
Columbia University
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Agenus Inc.
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Georgiamune Inc
Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
University of California, San Diego
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Ann & Robert H Lurie Children's Hospital of Chicago
FEMUS
Fudan University